Forward Pharma A Stock Retained Earnings
| FWPDelisted Stock | USD 2.56 0.00 0.00% |
Forward Pharma A fundamentals help investors to digest information that contributes to Forward Pharma's financial success or failures. It also enables traders to predict the movement of Forward Stock. The fundamental analysis module provides a way to measure Forward Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Forward Pharma stock.
Forward |
Forward Pharma A Company Retained Earnings Analysis
Forward Pharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Forward Pharma Retained Earnings | (9.1 M) |
Most of Forward Pharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Forward Pharma A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Forward Pharma A has a Retained Earnings of (9.1 Million). This is 100.98% lower than that of the Biotechnology sector and 109.39% lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.1% higher than that of the company.
Forward Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forward Pharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forward Pharma could also be used in its relative valuation, which is a method of valuing Forward Pharma by comparing valuation metrics of similar companies.Forward Pharma is currently under evaluation in retained earnings category among its peers.
Forward Fundamentals
| Return On Equity | -0.0083 | |||
| Return On Asset | -0.0342 | |||
| Current Valuation | (43.04 M) | |||
| Shares Outstanding | 7.09 M | |||
| Shares Owned By Institutions | 12.90 % | |||
| Number Of Shares Shorted | 4.51 K | |||
| Price To Earning | 0.13 X | |||
| Price To Book | 0.31 X | |||
| EBITDA | (1.89 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 70.77 M | |||
| Cash Per Share | 10.08 X | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 117.44 X | |||
| Book Value Per Share | 8.76 X | |||
| Cash Flow From Operations | (2.36 M) | |||
| Short Ratio | 1.78 X | |||
| Earnings Per Share | (0.27) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 37.0 | |||
| Beta | 1.38 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 71.41 M | |||
| Retained Earnings | (9.1 M) | |||
| Working Capital | 93.59 M | |||
| Current Asset | 99.8 M | |||
| Current Liabilities | 6.21 M | |||
| Z Score | 1.2 | |||
| Net Asset | 71.41 M |
About Forward Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Forward Pharma A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forward Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forward Pharma A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Forward Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Forward Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Forward Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Forward Stock
| 0.61 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.53 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.47 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.45 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.34 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
The ability to find closely correlated positions to Forward Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Forward Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Forward Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Forward Pharma A to buy it.
The correlation of Forward Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Forward Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Forward Pharma A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Forward Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Forward Stock
If you are still planning to invest in Forward Pharma A check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Forward Pharma's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |